Evidence map›Paper›PMID 33025742›Full record

ArticleMolecular oncology2020

TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas.

Francesca Maddalena, Valentina Condelli, Danilo Swann Matassa, Consiglia Pacelli, Rosella Scrima, Giacomo Lettini, Valeria Li Bergolis, Michele Pietrafesa, Fabiana Crispo, Annamaria Piscazzi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Francesca MaddalenaLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Valentina CondelliLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Danilo Swann MatassaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy.
Consiglia PacelliDepartment of Clinical and Experimental Medicine, University of Foggia, Italy.
Rosella ScrimaDepartment of Clinical and Experimental Medicine, University of Foggia, Italy.
Giacomo LettiniLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Valeria Li BergolisMedical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy.
Michele PietrafesaLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Fabiana CrispoLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Annamaria PiscazziMedical Oncology Unit, Department of Medical and Surgical Sciences, University of Foggia, Italy.
Giovanni StortoNuclear Medicine Unit, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.
Nazzareno CapitanioDepartment of Clinical and Experimental Medicine, University of Foggia, Italy.
Franca EspositoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Italy.
Matteo LandriscinaLaboratory of Pre-Clinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy.ORCID 0000-0003-0591-9799
Centro di Riferimento Oncologico della Basilicata · ITUniversity of Foggia · ITFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic rewiring is a mechanism of adaptation to unfavorable environmental conditions and tumor progression. TRAP1 is an HSP90 molecular chaperone upregulated in human colorectal carcinomas (CRCs) and responsible for downregulation of oxidative phosphorylation (OXPHOS) and adaptation to metabolic stress. The mechanism by which TRAP1 regulates glycolytic metabolism and the relevance of this regulation in resistance to EGFR inhibitors were investigated in patient-derived CRC spheres, human CRC cells, samples, and patients. A linear correlation was observed between TRAP1 levels and

Indexed as

Drug Resistance, NeoplasmWarburg Effect, OncologicCell Line, TumorCell RespirationCetuximabColorectal NeoplasmsEndoplasmic ReticulumEnzyme StabilityErbB ReceptorsFluorodeoxyglucose F18Glucose Transporter Type 1HSP90 Heat-Shock ProteinsHumansMitochondriaOxidation-ReductionPhenotypeBRAF protein, humanCetuximabEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18Glucose Transporter Type 1HSP90 Heat-Shock ProteinsPhosphofructokinase-1Protein Kinase InhibitorsProto-Oncogene Proteins B-rafTRAP1 protein, humancetuximabglycolysisoxidative phosphorylationphosphofructokinase 1TRAP1

Identifiers

PMID33025742
PMCPMC7718945
OpenAlexW3092512913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.